Publications by authors named "Rana Qawaqzeh"
Objective: Increased screen time has resulted in widespread computer vision syndrome (CVS) in the digital era. Medical students, who rely heavily on digital screens, are particularly at risk. Our study aims to evaluate the prevalence of CVS among Jordanian medical students, which is a gap in existing knowledge.
View Article and Find Full Text PDFSafety and efficacy of Rucaparib in the treatment of ovarian cancer and patients with BRCA mutation: a systematic review and meta-analysis of phase III randomized clinical trials.
Expert Rev Anticancer Ther
February 2024
Introduction: Our systematic review and meta-analysis aimed to evaluate the clinical efficacy and safety of Rucaparib, a PARP inhibitor (PARPi), in patients with ovarian cancer and BRCA mutation.
Methods: Online databases were comprehensively searched for all phase III Randomized trials that used Rucaparib therapy for ovarian cancer patients and patients having BRCA mutation. Efficacy results are progression-free survival and overall response rate in addition to addressing its safety concerns.
Article Synopsis
- The study aimed to evaluate the effectiveness and safety of tislelizumab, a PD-1 inhibitor, in treating patients with malignant solid tumors.
- Researchers conducted a meta-analysis of seven phase III randomized controlled trials involving 3,478 patients, focusing on various outcomes like overall response rate (ORR) and overall survival (OS).
- Results showed that tislelizumab significantly improved both ORR and disease control rate (DCR), supporting its use as a treatment for malignant solid tumors.
Article Synopsis
- The study aimed to assess the clinical effectiveness and safety of Capivasertib for patients with solid tumors by pooling data from four randomized controlled trials (RCTs).
- Results indicated that Capivasertib improved progression-free survival (PFS) and overall survival (OS) for the overall patient population, but did not significantly impact PFS in patients with specific genetic alterations (PI3K/AKT/PTEN).
- Safety analysis revealed a higher rate of treatment discontinuation due to adverse events when using Capivasertib compared to placebo, suggesting some risks alongside its antitumor benefits.